Impact of Infusion Therapies on Quality of Life in Advanced Parkinson's Disease

A high burden of motor and non-motor parkinsonian symptoms is known to have a significant negative impact on the quality of life (QoL) of people with Parkinson's disease (PD). Effective control of these symptoms with therapies that enable patients to maintain a good QoL is therefore a key treat...

ver descrição completa

Detalhes bibliográficos
Autores: Constantin, Viorelia Adelina, Szász, Jozsef A.|||0000-0003-1675-036X, Dulamea, Adriana Octaviana, Valkovic, Peter, Kulisevsky, Jaime|||0000-0003-4870-1431
Formato: artículo
Fecha de publicación:2023
País:España
Recursos:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:300814
Acesso em linha:https://ddd.uab.cat/record/300814
https://dx.doi.org/urn:doi:10.2147/NDT.S422717
Access Level:acceso abierto
Palavra-chave:Parkinson's disease
Infusion therapies
Motor symptoms
Patient-reported outcomes
Quality of life
id ES_184e6d411cf1fa3103d760f32d5ceed4
oai_identifier_str oai:ddd.uab.cat:300814
network_acronym_str ES
network_name_str España
repository_id_str
spelling Impact of Infusion Therapies on Quality of Life in Advanced Parkinson's DiseaseConstantin, Viorelia AdelinaSzász, Jozsef A.|||0000-0003-1675-036XDulamea, Adriana OctavianaValkovic, PeterKulisevsky, Jaime|||0000-0003-4870-1431Parkinson's diseaseInfusion therapiesMotor symptomsPatient-reported outcomesQuality of lifeA high burden of motor and non-motor parkinsonian symptoms is known to have a significant negative impact on the quality of life (QoL) of people with Parkinson's disease (PD). Effective control of these symptoms with therapies that enable patients to maintain a good QoL is therefore a key treatment goal in PD management. When symptom control can no longer be accomplished with oral or transdermal PD treatment regimens, device-aided therapies (DAT), namely levodopa and apomorphine infusion therapies, and deep brain stimulation, are valuable options to consider. DAT options may also help reduce pill burden and thereby improve compliance with treatment. Since PD therapy relies on symptomatic management, the efficacy and tolerability of any intervention is undoubtedly important, however the impact of different therapies on patient-related outcome measures, in particular health-related QoL, is also a critical consideration for those living with a chronic and disabling condition. This review discusses clinical evidence and ongoing research regarding the QoL benefits of levodopa and apomorphine infusion therapies from studies that have used validated QoL outcome measures. The data suggest that timing of these interventions is important to achieve optimal treatment effects, and that early initiation onto infusion therapies at the point when motor fluctuations emerge, and before patient QoL and functioning have significantly declined, may provide the best long-term outcomes. Healthcare professionals caring for people with PD should therefore discuss all available DAT options with them at an early stage in the course of their disease so they can make informed and timely choices that best suit them, their families and care network.Universitat Autònoma de Barcelona 22023-01-0120232023-01-01Article de revisióhttp://purl.org/coar/resource_type/c_dcae04bcVoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttps://ddd.uab.cat/record/300814https://dx.doi.org/urn:doi:10.2147/NDT.S422717reponame:Dipòsit Digital de Documents de la UABinstname:Universitat Autònoma de BarcelonaInglésengopen accesshttp://purl.org/coar/access_right/c_abf2Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.https://creativecommons.org/licenses/by-nc/4.0/info:eu-repo/semantics/openAccessoai:ddd.uab.cat:3008142026-06-06T12:50:31Z
dc.title.none.fl_str_mv Impact of Infusion Therapies on Quality of Life in Advanced Parkinson's Disease
title Impact of Infusion Therapies on Quality of Life in Advanced Parkinson's Disease
spellingShingle Impact of Infusion Therapies on Quality of Life in Advanced Parkinson's Disease
Constantin, Viorelia Adelina
Parkinson's disease
Infusion therapies
Motor symptoms
Patient-reported outcomes
Quality of life
title_short Impact of Infusion Therapies on Quality of Life in Advanced Parkinson's Disease
title_full Impact of Infusion Therapies on Quality of Life in Advanced Parkinson's Disease
title_fullStr Impact of Infusion Therapies on Quality of Life in Advanced Parkinson's Disease
title_full_unstemmed Impact of Infusion Therapies on Quality of Life in Advanced Parkinson's Disease
title_sort Impact of Infusion Therapies on Quality of Life in Advanced Parkinson's Disease
dc.creator.none.fl_str_mv Constantin, Viorelia Adelina
Szász, Jozsef A.|||0000-0003-1675-036X
Dulamea, Adriana Octaviana
Valkovic, Peter
Kulisevsky, Jaime|||0000-0003-4870-1431
author Constantin, Viorelia Adelina
author_facet Constantin, Viorelia Adelina
Szász, Jozsef A.|||0000-0003-1675-036X
Dulamea, Adriana Octaviana
Valkovic, Peter
Kulisevsky, Jaime|||0000-0003-4870-1431
author_role author
author2 Szász, Jozsef A.|||0000-0003-1675-036X
Dulamea, Adriana Octaviana
Valkovic, Peter
Kulisevsky, Jaime|||0000-0003-4870-1431
author2_role author
author
author
author
dc.contributor.none.fl_str_mv Universitat Autònoma de Barcelona
dc.subject.none.fl_str_mv Parkinson's disease
Infusion therapies
Motor symptoms
Patient-reported outcomes
Quality of life
topic Parkinson's disease
Infusion therapies
Motor symptoms
Patient-reported outcomes
Quality of life
description A high burden of motor and non-motor parkinsonian symptoms is known to have a significant negative impact on the quality of life (QoL) of people with Parkinson's disease (PD). Effective control of these symptoms with therapies that enable patients to maintain a good QoL is therefore a key treatment goal in PD management. When symptom control can no longer be accomplished with oral or transdermal PD treatment regimens, device-aided therapies (DAT), namely levodopa and apomorphine infusion therapies, and deep brain stimulation, are valuable options to consider. DAT options may also help reduce pill burden and thereby improve compliance with treatment. Since PD therapy relies on symptomatic management, the efficacy and tolerability of any intervention is undoubtedly important, however the impact of different therapies on patient-related outcome measures, in particular health-related QoL, is also a critical consideration for those living with a chronic and disabling condition. This review discusses clinical evidence and ongoing research regarding the QoL benefits of levodopa and apomorphine infusion therapies from studies that have used validated QoL outcome measures. The data suggest that timing of these interventions is important to achieve optimal treatment effects, and that early initiation onto infusion therapies at the point when motor fluctuations emerge, and before patient QoL and functioning have significantly declined, may provide the best long-term outcomes. Healthcare professionals caring for people with PD should therefore discuss all available DAT options with them at an early stage in the course of their disease so they can make informed and timely choices that best suit them, their families and care network.
publishDate 2023
dc.date.none.fl_str_mv 2
2023-01-01
2023
2023-01-01
dc.type.none.fl_str_mv Article de revisió
http://purl.org/coar/resource_type/c_dcae04bc
VoR
http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://ddd.uab.cat/record/300814
https://dx.doi.org/urn:doi:10.2147/NDT.S422717
url https://ddd.uab.cat/record/300814
https://dx.doi.org/urn:doi:10.2147/NDT.S422717
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by-nc/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by-nc/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Dipòsit Digital de Documents de la UAB
instname:Universitat Autònoma de Barcelona
instname_str Universitat Autònoma de Barcelona
reponame_str Dipòsit Digital de Documents de la UAB
collection Dipòsit Digital de Documents de la UAB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869403977524707328
score 15.812429

Registos relacionados